Recombinant C1 inhibitor in the prevention of severe COVID-19: a randomized, open-label, multi-center phase IIa trial
Urwyler et al., Frontiers in Immunology, doi:10.3389/fimmu.2023.1255292
https://c19early.org/urwyler.html